What is the official website of Takeda Oncology ?

The official website of Takeda Oncology is http://www.takedaoncology.com.

What is Takeda Oncology's cybersecurity risk score?

Takeda Oncology has an AI-generated cybersecurity risk score of 764 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Takeda Oncology experienced?

According to Rankiteo, Takeda Oncology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Takeda Oncology been affected by any supply chain cyber incidents ?

According to Rankiteo, Takeda Oncology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Takeda Oncology have SOC 2 Type 1 certification ?

According to Rankiteo, Takeda Oncology is not certified under SOC 2 Type 1.

Does Takeda Oncology have SOC 2 Type 2 certification ?

According to Rankiteo, Takeda Oncology does not hold a SOC 2 Type 2 certification.

Does Takeda Oncology comply with GDPR ?

According to Rankiteo, Takeda Oncology is not listed as GDPR compliant.

Does Takeda Oncology have PCI DSS certification ?

According to Rankiteo, Takeda Oncology does not currently maintain PCI DSS compliance.

Does Takeda Oncology comply with HIPAA ?

According to Rankiteo, Takeda Oncology is not compliant with HIPAA regulations.

Does Takeda Oncology have ISO 27001 certification ?

According to Rankiteo,Takeda Oncology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Takeda Oncology operate in ?

Takeda Oncology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Takeda Oncology have ?

Takeda Oncology employs approximately 1,665 people worldwide.

Does Takeda Oncology own any subsidiaries ?

Takeda Oncology presently has no subsidiaries across any sectors.

How many LinkedIn followers does Takeda Oncology have ?

Takeda Oncology's official LinkedIn profile has approximately 159,520 followers.

What is the NAICS classification code for Takeda Oncology ?

Takeda Oncology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Takeda Oncology have a Crunchbase profile ?

No, Takeda Oncology does not have a profile on Crunchbase.

Does Takeda Oncology have a LinkedIn profile ?

Yes, Takeda Oncology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/takedaoncology.

How many cybersecurity incidents has Takeda Oncology experienced ?

As of June 26, 2026, Rankiteo reports that Takeda Oncology has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Takeda Oncology have ?

Takeda Oncology has an estimated 5,696 peer or competitor companies worldwide.

What types of cybersecurity incidents has Takeda Oncology faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Takeda Oncology

Boost Score +25 with badge (5 left)

764

/1000

Fair

789

/1000

Fair

Takeda Oncology Vendor Cyber Rating & Cyber Score

takedaoncology.com

Add Your Compliance Badge

Takeda Oncology is the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited. At Takeda, we are united by our aspiration to cure cancer. Drawing on decades of leadership in oncology, we strive to develop innovative treatments that make a difference in the lives of people living with cancer. Our research and development efforts are focused on advancing medicines for thoracic, gastrointestinal and hematologic cancers by leveraging modalities best suited to treat these diseases. Our in-house expertise and innovation are complemented by our valued partners. We fuel these relationships with respect, scientific rigor and a shared commitment to address the most urgent needs of patients. Our diverse global team fosters

Takeda Oncology A.I CyberSecurity Scoring

Scoring History

Takeda Oncology

Takeda Oncology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Takeda Oncology

Breach

1/2024

BIO201072825

Loading…

A.I.

Takeda Oncology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Takeda Oncology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incident Types Takeda Oncology vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incident History - Takeda Oncology (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Takeda Oncology Subsidiaries

Takeda Oncology

Pharmaceutical Manufacturing

Website: http://www.takedaoncology.com

Company Size: 1,665

TakedaPharmaceutical Manufacturing

BioLife Plasma ServicesPharmaceutical Manufacturing

Takeda Canada Inc.Pharmaceutical Manufacturing

TAKEDA IBDpointServizi benessere e fitness

Dengue AcademyArzneimittelherstellung

ARIAD Pharmaceuticals, Inc.Pharmaceutical Manufacturing

Loading…

Takeda Oncology Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Takeda Oncology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 28, 2026 08:00 AM

Hexagon Health congratulates Brian Nwokorie, PharmD at Takeda Oncology on being named to MM+M’s 40 Under 40 list

NEW YORK, NY, UNITED STATES, January 28, 2026 /EINPresswire.com/ — Hexagon Health is proud to congratulate Brian Nwokorie, PharmD, Global Brand Lead for...

Read Article

October 22, 2025 07:00 AM

China's Innovent signs cancer therapy deal with Japan's Takeda

Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology...

Read Article

October 21, 2025 07:00 AM

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive...

Read Article

September 27, 2024 07:00 AM

Tempus AI expands oncology collaboration with Takeda

The collaboration aims to utilise Tempus' real-world data and biological modelling to enhance the development of Takeda's oncology treatment portfolio.

Read Article

September 24, 2024 07:00 AM

Takeda’s FRUZAQLA gains approval in Japan for colorectal cancer

Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer (CRC).

Read Article

October 03, 2023 07:00 AM

Takeda withdraws cancer drug Exkivity after Phase III trial failure

Takeda Pharmaceuticals has started the process for a voluntary withdrawal of Exkivity (mobocertinib) in the US after a confirmatory Phase III trial failed to...

Read Article

January 26, 2023 08:00 AM

Takeda One Ups Pfizer, Moderna with 600,000 SF R&D Office in Cambridge

Takeda Invests in 600000-square-foot facility in Kendall Square, next to Pfizer and Moderna for research and development.

Read Article

January 09, 2017 08:00 AM

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56785

SUMMARY

FlatPress versions prior to commit 10be83c, contains a stored cross-site scripting vulnerability in comment and contact forms where name, URL, and email fields are rendered without proper output encoding in Smarty templates. Attackers can inject arbitrary HTML and JavaScript through these fields to execute malicious scripts in browsers of viewers including administrators, or bypass URL scheme validation to inject javascript: or data: URIs.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 8.2)

cvss3

Base Score: 8.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-54588

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 use the attacker-controlled `HTTP_HOST` request header as the authoritative source for building callback URLs in its OIDC, SAML, and logout authentication flows without any validation. An unauthenticated attacker can poison the `redirect_uri` sent to the Identity Provider, causing the IdP to redirect the victim's authorization code to an attacker-controlled server - resulting in full account takeover with no credentials required. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-48493

SUMMARY

Snipe-IT is an IT asset/license management system. In versions prior to 8.6.0, a user with only users.edit can send a PATCH to /api/v1/users/{their_own_id} and grant themselves any permission except admin and superuser — for example `assets.view`, `assets.create`, `reports.view`, import, etc. The issue is patched in version 8.6.0.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:H/A:N

Impact Score

4.2

Exploitability

1.2

REFERENCES

CVE-2026-47693

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 are vulnerable to CSV Injection (Formula Injection) in its log export functionality. User-controlled data — specifically the username field — is written to exported CSV files without sanitizing formula trigger characters (=, +, -, @). When an administrator exports activity logs and opens the resulting CSV in a spreadsheet application (Microsoft Excel, LibreOffice Calc, Google Sheets), any formula stored in a username is executed by the application. This can be used for phishing attacks against administrators or data exfiltration. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 6.9)

cvss3

Base Score: 6.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:H/I:L/A:N

Impact Score

4.7

Exploitability

1.7

REFERENCES

CVE-2026-12164

SUMMARY

Fortra File Integrity Monitoring (FIM), formerly Tripwire Enterprise, versions prior to 9.4.0 may assign incorrect or elevated effective permissions to users created by the tetool import command while FIM is running, particularly when the import also creates or changes roles or role-permission relationships.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 4.4)

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

0.8

REFERENCES

https://www.fortra.com/security/advisories/product-security/fi-2026-010

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…